Comparative Pharmacology
Head-to-head clinical analysis: CIPROFLOXACIN EXTENDED RELEASE versus GEMIFLOXACIN MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPROFLOXACIN EXTENDED RELEASE versus GEMIFLOXACIN MESYLATE.
CIPROFLOXACIN EXTENDED RELEASE vs GEMIFLOXACIN MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication, transcription, repair, and recombination.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, blocking DNA replication and transcription.
500-1000 mg orally once daily for 7-14 days; extended-release tablet must be taken whole with a meal.
320 mg orally once daily for 7-14 days
None Documented
None Documented
Terminal elimination half-life approximately 11 hours, ranging from 10-14 hours in patients with normal renal function. Prolonged in renal impairment; requires dose adjustment.
Terminal elimination half-life 7–9 hours (mean 8.2 h) in healthy adults; prolonged in renal impairment (e.g., 15–22 h in severe renal impairment).
Primarily renal excretion (50-70% unchanged drug via glomerular filtration and tubular secretion); 15-25% metabolized; 20-35% fecal elimination via biliary secretion and intestinal epithelium.
Renal: ~61% as unchanged drug, ~7% as glucuronide; Fecal/biliary: ~28% as unchanged drug and metabolites.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic